CelluTarget · Multifocal Motor Neuropathy · Treatments
◎ Investigational

Rituximab (off-label)

2
Evidence entries
0
Clinical trials
Overview
Treatment Details
Mechanism of Action
Anti-CD20 monoclonal antibody depleting B cells; used off-label, mainly in antibody-associated variants.
Dosing Notes
Dosing individualized; not a first-line therapy.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Low ConfidenceBased on case reports, expert opinion, or early-phase data only
EFNS/PNS guideline: rituximab is a possible immunosuppressive option (among several) if IVIG is not or not sufficiently effective. No placebo-controlled trials exist.
Verified Jul 2026
Peer Reviewed
EFNS/PNS Guideline on management of multifocal motor neuropathy (joint task force report)
Published March 2006
View source ↗
Case series of IgM-antibody-associated polyneuropathy patients (including MMN) treated with rituximab; reported benefit in a subset. Case-level evidence only, not a controlled trial.
Verified Jul 2026
Peer Reviewed
Treatment of IgM antibody associated polyneuropathies using rituximab (case series)
Published April 2003
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.